As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

There’s plenty of empty lab space around Greater Boston these days, and a lot of competition for life-science tenants. Now ...

Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Read why I think DNA ...

Ginkgo already canceled its plans to move into Biofab1, a new 260,000-square-foot lab data center it's been building near its ...

Ginkgo Bioworks falls short on Q4 revenue and projects weak 2025 guidance. Learn about DNA stock's valuation risks, cash ...

Some creatures have barely changed for millions of years! These “living fossils” offer a glimpse into Earth’s distant past, defying evolution while surviving through shifting climates and mass ...

Cell Engineering revenue $110M-$130M with potential upside from the recent launch of Tools offerings Ginkgo expects Biosecurity ...

Discover the incredible resilience of the ginkgo tree, a living fossil that survived nuclear devastation and thrives ...

Ginkgo Bioworks (DNA) is down -12.5%, or -$1.29 to $9.00.Discover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and ...

Full Year 2024 Results Key Financial Results Revenue: US$227.0m (down 9.7% ...

Ginkgo’s headquarters at 27 Drydock Ave. spans some 320,000 square feet, with leases that run from 2030 through 2036. The ...